Zhejiang Huahai Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is LINAGLIPTIN, with a corresponding US DMF Number 28766.
Remarkably, this DMF maintains an Active status since its submission on November 19, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 09, 2015, and payment made on December 16, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II